Matches in SemOpenAlex for { <https://semopenalex.org/work/W2519634482> ?p ?o ?g. }
- W2519634482 endingPage "2561" @default.
- W2519634482 startingPage "2532" @default.
- W2519634482 abstract "This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks and strokes. It explains how the evidence that is available from randomised controlled trials yields reliable information about both the efficacy and safety of statin therapy. In addition, it discusses how claims that statins commonly cause adverse effects reflect a failure to recognise the limitations of other sources of evidence about the effects of treatment. Large-scale evidence from randomised trials shows that statin therapy reduces the risk of major vascular events (ie, coronary deaths or myocardial infarctions, strokes, and coronary revascularisation procedures) by about one-quarter for each mmol/L reduction in LDL cholesterol during each year (after the first) that it continues to be taken. The absolute benefits of statin therapy depend on an individual's absolute risk of occlusive vascular events and the absolute reduction in LDL cholesterol that is achieved. For example, lowering LDL cholesterol by 2 mmol/L (77 mg/dL) with an effective low-cost statin regimen (eg, atorvastatin 40 mg daily, costing about £2 per month) for 5 years in 10 000 patients would typically prevent major vascular events from occurring in about 1000 patients (ie, 10% absolute benefit) with pre-existing occlusive vascular disease (secondary prevention) and in 500 patients (ie, 5% absolute benefit) who are at increased risk but have not yet had a vascular event (primary prevention). Statin therapy has been shown to reduce vascular disease risk during each year it continues to be taken, so larger absolute benefits would accrue with more prolonged therapy, and these benefits persist long term. The only serious adverse events that have been shown to be caused by long-term statin therapy-ie, adverse effects of the statin-are myopathy (defined as muscle pain or weakness combined with large increases in blood concentrations of creatine kinase), new-onset diabetes mellitus, and, probably, haemorrhagic stroke. Typically, treatment of 10 000 patients for 5 years with an effective regimen (eg, atorvastatin 40 mg daily) would cause about 5 cases of myopathy (one of which might progress, if the statin therapy is not stopped, to the more severe condition of rhabdomyolysis), 50-100 new cases of diabetes, and 5-10 haemorrhagic strokes. However, any adverse impact of these side-effects on major vascular events has already been taken into account in the estimates of the absolute benefits. Statin therapy may cause symptomatic adverse events (eg, muscle pain or weakness) in up to about 50-100 patients (ie, 0·5-1·0% absolute harm) per 10 000 treated for 5 years. However, placebo-controlled randomised trials have shown definitively that almost all of the symptomatic adverse events that are attributed to statin therapy in routine practice are not actually caused by it (ie, they represent misattribution). The large-scale evidence available from randomised trials also indicates that it is unlikely that large absolute excesses in other serious adverse events still await discovery. Consequently, any further findings that emerge about the effects of statin therapy would not be expected to alter materially the balance of benefits and harms. It is, therefore, of concern that exaggerated claims about side-effect rates with statin therapy may be responsible for its under-use among individuals at increased risk of cardiovascular events. For, whereas the rare cases of myopathy and any muscle-related symptoms that are attributed to statin therapy generally resolve rapidly when treatment is stopped, the heart attacks or strokes that may occur if statin therapy is stopped unnecessarily can be devastating." @default.
- W2519634482 created "2016-09-23" @default.
- W2519634482 creator A5013184354 @default.
- W2519634482 creator A5014267007 @default.
- W2519634482 creator A5015704931 @default.
- W2519634482 creator A5018419311 @default.
- W2519634482 creator A5022288501 @default.
- W2519634482 creator A5025156367 @default.
- W2519634482 creator A5026262569 @default.
- W2519634482 creator A5029838434 @default.
- W2519634482 creator A5030243760 @default.
- W2519634482 creator A5030250235 @default.
- W2519634482 creator A5033502820 @default.
- W2519634482 creator A5039985378 @default.
- W2519634482 creator A5040169514 @default.
- W2519634482 creator A5041941850 @default.
- W2519634482 creator A5048397189 @default.
- W2519634482 creator A5049652855 @default.
- W2519634482 creator A5056315210 @default.
- W2519634482 creator A5060735505 @default.
- W2519634482 creator A5065348937 @default.
- W2519634482 creator A5066653118 @default.
- W2519634482 creator A5071903285 @default.
- W2519634482 creator A5072011562 @default.
- W2519634482 creator A5075162144 @default.
- W2519634482 creator A5077916068 @default.
- W2519634482 creator A5079993549 @default.
- W2519634482 creator A5087095202 @default.
- W2519634482 creator A5090621185 @default.
- W2519634482 creator A5091595592 @default.
- W2519634482 date "2016-11-01" @default.
- W2519634482 modified "2023-10-14" @default.
- W2519634482 title "Interpretation of the evidence for the efficacy and safety of statin therapy" @default.
- W2519634482 cites W127809968 @default.
- W2519634482 cites W1423581981 @default.
- W2519634482 cites W1494949771 @default.
- W2519634482 cites W1500847299 @default.
- W2519634482 cites W1523152575 @default.
- W2519634482 cites W1546258268 @default.
- W2519634482 cites W1573777214 @default.
- W2519634482 cites W1583447426 @default.
- W2519634482 cites W1586334234 @default.
- W2519634482 cites W1586699954 @default.
- W2519634482 cites W1593008417 @default.
- W2519634482 cites W1593442063 @default.
- W2519634482 cites W1604547439 @default.
- W2519634482 cites W1607804102 @default.
- W2519634482 cites W1628749699 @default.
- W2519634482 cites W166112863 @default.
- W2519634482 cites W173808884 @default.
- W2519634482 cites W179406719 @default.
- W2519634482 cites W1856460279 @default.
- W2519634482 cites W1922625321 @default.
- W2519634482 cites W1954929705 @default.
- W2519634482 cites W1964694228 @default.
- W2519634482 cites W1965963768 @default.
- W2519634482 cites W1966988082 @default.
- W2519634482 cites W1968604782 @default.
- W2519634482 cites W1970357164 @default.
- W2519634482 cites W1974711414 @default.
- W2519634482 cites W1975357252 @default.
- W2519634482 cites W1976326436 @default.
- W2519634482 cites W1976358806 @default.
- W2519634482 cites W1977915442 @default.
- W2519634482 cites W1978205439 @default.
- W2519634482 cites W1979885794 @default.
- W2519634482 cites W1980185258 @default.
- W2519634482 cites W1981501248 @default.
- W2519634482 cites W1982914740 @default.
- W2519634482 cites W1983592112 @default.
- W2519634482 cites W1984058728 @default.
- W2519634482 cites W1984262040 @default.
- W2519634482 cites W1984454461 @default.
- W2519634482 cites W1985075719 @default.
- W2519634482 cites W1985903522 @default.
- W2519634482 cites W1986818118 @default.
- W2519634482 cites W1987341486 @default.
- W2519634482 cites W1990030978 @default.
- W2519634482 cites W1995622206 @default.
- W2519634482 cites W1996015815 @default.
- W2519634482 cites W1998569580 @default.
- W2519634482 cites W1998939122 @default.
- W2519634482 cites W2002251042 @default.
- W2519634482 cites W2003097193 @default.
- W2519634482 cites W2006614650 @default.
- W2519634482 cites W2006941271 @default.
- W2519634482 cites W2007954685 @default.
- W2519634482 cites W2008661724 @default.
- W2519634482 cites W2010033213 @default.
- W2519634482 cites W2012789522 @default.
- W2519634482 cites W2013489663 @default.
- W2519634482 cites W2015672635 @default.
- W2519634482 cites W2015712245 @default.
- W2519634482 cites W2016464689 @default.
- W2519634482 cites W2017329532 @default.
- W2519634482 cites W2017872978 @default.
- W2519634482 cites W2018719851 @default.
- W2519634482 cites W2019071303 @default.